Related Experiment Video
Updated: Jun 12, 2026
An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
Metachromatic leukodystrophy--an update
V Gieselmann1, I Krägeloh-Mann
1Department of Physiology, University of Bonn, Germany.
Abstract:
Metachromatic leukodystrophy (MLD) is a rare lysosomal sphingolipid storage disorder, caused by a deficiency of arylsulfatase A (ASA). It is inherited in an autosomal recessive way, among Caucasians three causing alleles are frequent. Demyelination is the hallmark of MLD. Interest in the disease has increased as therapeutic options such as stem cell transplantation, enzyme replacement and gene therapy are topics of current research. A late-infantile (onset before 3 years of age), a juvenile form (onset before 16 years) and an adult form are usually distinguished. Rapid motor decline is typical for the first and also the second forms, the second may be preceded by cognitive and behavioural problems, which mainly characterize the adult form. There is evidence for a genotype-phenotype correlation: patients homozygous for alleles which do not allow the expression of any enzyme activity (null-allele) suffer from the late infantile form; heterozygosity for a null allele and a non-null allele are more associated with the juvenile form and homozygosity for non-null alleles is more frequent in the most attenuated adult onset form.
Insights
Metachromatic leukodystrophy (MLD) is a rare genetic disorder affecting the nervous system due to arylsulfatase A deficiency. Research is advancing therapeutic options like gene therapy and enzyme replacement for MLD.
Area of Science:
- * Neuroscience
- * Genetics
- * Biochemistry
Background:
- * Metachromatic leukodystrophy (MLD) is a rare autosomal recessive lysosomal sphingolipid storage disorder.
- * It is characterized by demyelination, resulting from a deficiency in the enzyme arylsulfatase A (ASA).
- * MLD presents in various forms, including late-infantile, juvenile, and adult onset, with distinct clinical progressions.
Purpose of the Study:
- * To summarize the current understanding of Metachromatic Leukodystrophy (MLD).
- * To highlight the genetic basis and phenotypic variations of MLD.
- * To underscore the emerging therapeutic strategies for MLD.
Main Methods:
- * Review of existing literature on Metachromatic Leukodystrophy.
- * Analysis of genotype-phenotype correlations in MLD patients.
- * Summary of current research in therapeutic interventions.
Main Results:
- * MLD is caused by arylsulfatase A (ASA) deficiency, with specific frequent alleles in Caucasian populations.
- * Clinical manifestations vary, with rapid motor decline in early-onset forms and cognitive issues in adult-onset MLD.
- * A correlation exists between genotype and phenotype, influencing disease severity and onset.
Conclusions:
- * Therapeutic options including stem cell transplantation, enzyme replacement, and gene therapy are under active investigation for MLD.
- * Understanding the genotype-phenotype correlation is crucial for predicting disease progression and tailoring treatments.
- * Continued research is vital for developing effective interventions for this rare lysosomal storage disorder.
